Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | FYN | P06241 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31057644 | 0.85 | KMO (0.45) | FYNNPC1ALDH1A1HPGDTSHR | |
| SCHEMBL31400342 | 0.77 | FYN (0.43) | FYNNPC1SMN1; SMN2TSHR | |
| SCHEMBL31057633 | 0.75 | FYN (0.42) | FYNSMN1; SMN2 | |
| SCHEMBL20839754 | 0.73 | SPR (0.44) | NPC1ALDH1A1HPGDTSHRL3MBTL1 | |
| SCHEMBL19895171 | 0.73 | NPC1 (0.71) | SLC6A3SLC6A2NPC1ALDH1A1HPGD | |
| SCHEMBL27801682 | 0.72 | ABL1 (0.51) | SLC6A3SLC6A2NPC1ALDH1A1HPGD | |
| SCHEMBL31636902 | 0.72 | LDHA (0.52) | SLC6A3SLC6A2NPC1ALDH1A1HPGD | |
| SCHEMBL20839878 | 0.72 | KMT2A (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10960418 | 0.70 | CA12 (0.47) | SLC6A3SLC6A2CNR2F2RL3L3MBTL1 | |
| SCHEMBL30285060 | 0.70 | SLC6A3 (0.69) | SLC6A3SLC6A2NPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638437-A1 | PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | Boehringer Ingelheim International GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250059165-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20240246981-A1 | PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-07-25 | — | — | US | disclosed |
| WO-2024133014-A1 | PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246981-A1 | PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GGCT | SLC6A3 1496/4885FYN 2746/4885SLC6A2 1364/4885 |
| US-20250059165-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GLUL | SLC6A3 3489/4885FYN 2977/4885SLC6A2 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.